|Chemical and physical data|
|Molar mass||274.4 g/mol g·mol−1|
|3D model (JSmol)|
|Melting point||181 °C (358 °F)|
|(what is this?)|
The mechanism that produces the purported hallucinogenic and entheogenic effects of 5-MeO-DiPT is thought to result primarily from 5-HT2A receptor agonism, although additional mechanisms of action such as monoamine oxidase inhibition (MAOI) may be involved also. The strongest receptor binding affinity for 5-MeO-DiPT is at the 5-HT1A receptor.
Excessive doses have caused clinical intoxication, characterized by nausea, vomiting, agitation, hypotension, mydriasis, tachycardia and hallucinations, in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man and another one died 3–4 hours after an apparent rectal overdose. At least one death has been attributed to consumption of 5-MeO-DiPT.
Drug prohibition laws
As of October 2015 5-MeO-DiPT is a controlled substance in China.
Illegal since February 2004.
Illegal since September 1999.
Illegal since February 2003.
Illegal since April 2005.
Illegal since early 2006.
Sveriges riksdags health ministry Statens folkhälsoinstitut classified 5-MeO-DiPT as "health hazard" under the act Lagen om förbud mot vissa hälsofarliga varor (translated Act on the Prohibition of Certain Goods Dangerous to Health) as of Oct 1, 2004, in their regulation SFS 2004:696 listed as 5-metoxi-N,N-diisopropyltryptamin (5-MeO-DIPT), making it illegal to sell or possess.
On April 4, 2003, the United States DEA added both 5-MeO-DiPT and alpha-methyltryptamine (AMT) to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004. Prior to its prohibition in the U.S., 5-MeO-DiPT was sold online alongside psychoactive analogues such as DiPT, and DPT, neither of which have yet been expressly outlawed.
- Narimatsu, Shizuo; Yonemoto, Rei; Saito, Keita; Takaya, Kazuo; Kumamoto, Takuya; Ishikawa, Tsutomu; Asanuma, Masato; Funada, Masahiko; Kiryu, Kimio; Naito, Shinsaku; Yoshida, Yuzo; Yamamoto, Shigeo; Hanioka, Nobumitsu (2006). "Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes". Biochemical Pharmacology. 71 (9): 1377. doi:10.1016/j.bcp.2006.01.015. PMID 16510126.
- Nagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology. 559 (2–3): 132–7. doi:10.1016/j.ejphar.2006.11.075. PMID 17223101.
- Ray TS (2 February 2010). "Psychedelics and the Human Receptorome". PLoS One. 5 (2): e9019. doi:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.
- Noworyta-Sokołowska, Karolina; Kamińska, Katarzyna; Kreiner, Grzegorz; Rogóż, Zofia; Gołembiowska, Krystyna (2016). "Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats". Neurotoxicity Research. 30 (4): 606–619. doi:10.1007/s12640-016-9654-0. ISSN 1029-8428. PMC 5047954. PMID 27461536.
- R. Baselt (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 975–976.
- Tanaka, Einosuke; Kamata, Tooru; Katagi, Munehiro; Tsuchihashi, Hitoshi; Honda, Katsuya (2006). "A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy". Forensic Science International. 163 (1–2): 152–4. doi:10.1016/j.forsciint.2005.11.026. PMID 16406422.
- "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
- "notisum.se" (PDF). Archived (PDF) from the original on 2013-09-29. Retrieved 2013-09-06.